Vincenzo F.
- Country
- Italy
- Department
- U.O. Oncologia Medica
Research Overview
- Switch Maintenance with Paclitaxel, Ramucirumab and Tislelizumab vs Continued Chemotherapy plus Tislelizumab in HER2‑negative, PD‑L1‑positive Gastroesophageal Adenocarcinoma
- Phase II Randomized Trial of Modified FOLFIRINOX and FOLFOX Regimens in Locally Advanced or Metastatic Small Bowel Adenocarcinoma
- Phase III Randomized Trial of mFOLFIRINOX Versus mFOLFOX in Adjuvant Treatment of High-Risk Stage III Colon Cancer
Data & Insights
Has run more than one trial at 109 of 282 partner sites.
Specializations
Advanced Colorectal Cancer Treatment
This investigator specializes in treating metastatic colorectal cancer with particular focus on developing innovative therapeutic sequences and combinations.
- RAS/BRAF wild-type tumors
- KRAS G12C mutations
- Targeted therapy combinations
The research extends to evaluating treatment options for patients unsuitable for intensive chemotherapy regimens.
Molecular-Guided Therapy
The investigator focuses on precision medicine approaches in colorectal cancer treatment, incorporating molecular biomarkers for treatment selection.
- Circulating tumor DNA analysis
- MGMT silencing assessment
- HER2 targeted interventions
Their work emphasizes personalized treatment strategies based on molecular characteristics.
Early-Stage Disease Management
The investigator conducts research in adjuvant therapy optimization for early-stage colorectal cancer patients.
- High-risk stage II treatment
- Stage III disease management
- Post-operative treatment intensification
Their research includes novel approaches to minimize disease recurrence after surgery.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.